No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SWTX240517C70000
- 0.75
- -0.30-28.57%
15min DelayClose May 10 15:59 ET
0.75High0.75Low
0.75Open1.05Pre Close2 Volume3 Open Interest70.00Strike Price150.00Turnover287.26%IV73.03%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.75Time Value100Contract SizeAmericanOptions Type0.1143Delta0.0123Gamma54.52Leverage Ratio-0.2235Theta0.0007Rho6.23Eff Leverage0.0106Vega
Intraday
- 5D
- 1D
News
Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus estimated revenue n
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ
Express News | HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target
SpringWorks Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 64.04% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/06/2024 66.26% JP Morgan $74 → $75 Mai
Analysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)
Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference
The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:Financial Performance:SpringWorks Therapeutics reported revenue of $21 million after the succes
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$SpringWorks Therapeutics(SWTX.US$ nice go down so i can get some
JP Morgan analysts believe Ogsiveo's broad label is an outright victory for SpringWorks. They see the drug's global blockbuster potential and notice the company's research into its applicability to certain ovarian tumors and multiple myeloma.
1
1
$SpringWorks Therapeutics(SWTX.US$ SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors 1 MINUTE AGO, 6:04 PM EST VIA GLOBENEWSWIRE![]()
2
Read more